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Background: A phase III trial demonstrated that cetuximab is the ﬁrst agent in 30 years to improve survival when
added to platinum-based chemotherapy (platinum-ﬂuorouracil) ﬁrst line for recurrent and/or metastatic squamous cell
carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of
life (QoL).
Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-
Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H&N35) module were used to assess QoL.
Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H&N35) patients completed at least one
evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum–ﬂuorouracil plus cetuximab
were not signiﬁcantly worse than those for platinum–ﬂuorouracil. Pattern-mixture analysis demonstrated a signiﬁcant
improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences
in the social functioning scale. For QLQ-H&N35, the mean score for the cetuximab arm was not signiﬁcantly worse
than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores
signiﬁcantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating).
Conclusion: Adding cetuximab to platinum–ﬂuorouracil does not adversely affect the QoL of patients with recurrent
and/or metastatic SCCHN.
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introduction
For patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck (SCCHN), platinum has been
an integral part of palliative care for about the past 30 years.
The median survival time of these patients remains around 6–7
months [1]. In 2008, the EXTREME (Erbitux in ﬁrst-line
treatment of recurrent or metastatic head and neck cancer) trial
(n = 442) demonstrated that adding the immunoglobulin G1
epidermal growth factor receptor (EGFR)-targeting
monoclonal antibody cetuximab to ﬁrst-line platinum
(cisplatin or carboplatin) and 5-ﬂuorouracil (5-FU)
signiﬁcantly improved outcome compared with platinum-
based chemotherapy alone for patients with recurrent and/or
metastatic SCCHN [2]. Adding cetuximab to platinum-based
chemotherapy signiﬁcantly prolonged median overall survival
[7.4 versus 10.1 months; hazard ratio (HR) for death 0.80,
95% conﬁdence interval (CI) 0.64–0.99; P = 0.04) and
progression-free survival (PFS; 3.3 versus 5.6 months; HR for
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signiﬁcantly increased the response rate from 20% to 36% (P <
0.001) [2]. This is the ﬁrst randomized trial in 30 years to show
a beneﬁt of adding a new drug to platinum-based therapy over
platinum-based chemotherapy alone.
Cetuximab is generally well tolerated in SCCHN [2–6], the
most common adverse event being skin reactions. In the
EXTREME trial, the incidence of grade 3/4 events was similar
between the treatment arms, with the exception of skin
reactions (9% versus <1%; P < 0.001), sepsis (4% versus <1%;
P = 0.02), and hypomagnesemia (5% versus 1%; P = 0.05),
which were higher in the combined chemotherapy–cetuximab
arm [2]. The use of cetuximab in patients with metastatic
colorectal cancer [7–9] or when added to radiotherapy for
patients with locally advanced SCCHN [10] appears not to
adversely affect patients’ quality of life (QoL). A secondary
objective of the EXTREME trial was to compare the QoL of
patients receiving platinum–ﬂuorouracil plus cetuximab with
that of patients receiving platinum–ﬂuorouracil alone for
recurrent and/or metastatic SCCHN.
patients and methods
study design and treatment
The methods and results for the phase III EXTREME trial have
previously been described [2]. The protocol was approved by the
independent ethics committees of each participating center and by the
authorities in each country and the trial was conducted in accordance
with the Declaration of Helsinki. All patients provided oral and written
informed consent.
Patients with histologically or cytologically conﬁrmed recurrent and/or
metastatic SCCHN (excluding nasopharyngeal carcinoma) not suitable for
local therapy and a Karnofsky performance score (KPS) of ‡70 were
randomly assigned to receive cisplatin (100 mg/m
2 as a 1-h i.v. infusion on
day 1) or carboplatin [AUC (area under the curve for drug concentration as
a function of time) 5 mgmin/ml by 1-h i.v. infusion on day 1] and an
infusion of 5-FU (1000 mg/m
2 per day for 4 days) every 3 weeks, with or
without cetuximab [initial dose of 400 mg/m
2 (2-h i.v. infusion) followed
by subsequent weekly doses of 250 mg/m
2 (1-h i.v. infusion), ending at least
1 h before the start of chemotherapy] [2]. Treatment was continued for
a maximum of six cycles of chemotherapy. After six cycles, patients in the
cetuximab arm who had at least stable disease received cetuximab
monotherapy until disease progression or unacceptable toxicity, whereas
patients in the chemotherapy-alone arm received no further active
treatment but remained in the study until disease progression.
Randomization was stratiﬁed according to receipt or nonreceipt of previous
chemotherapy and KPS (<80 versus ‡80).
The primary objective of the trial was to assess the effects of treatment on
overall survival. QoL was a secondary objective.
QoL analysis
Two European Organisation for Research and Treatment of Cancer
(EORTC) multidimensional QoL questionnaires were used [11, 12].
The QoL Questionnaire-Core 30 (QLQ-C30 version 3.0) is a cancer-
speciﬁc, self-administered questionnaire with 30 questions and comprises
an overall global health status/QoL scale; ﬁve functional scales—physical,
role, emotional, cognitive, and social functioning scales; three multi-item
symptom scales—fatigue, nausea/vomiting, and pain; and six single-item
symptom scales—dyspnea, insomnia, appetite loss, constipation, diarrhea,
and ﬁnancial difﬁculties.
The QLQ-Head and Neck 35 (QLQ-H&N35) module is a head and neck
cancer-speciﬁc module with 35 questions and comprises 7 multi-item
symptom scales—pain, problems with swallowing, sense, speech, social
eating, social contact, and reduced sexuality—and 11 single-item symptom
scales—problems with teeth, opening the mouth, dry mouth, sticky saliva,
coughing, feeling ill, requirement for analgesics, nutritional supplements,
use of a feeding tube, weight loss, and weight gain.
QoL assessments were conducted at each study site where appropriate
validated translations of the instruments were available. The scores of the
scales were calculated according to the procedure deﬁned in the EORTC
QLQ-C30 scoring manual [11]. All the scores were derived from mutually
exclusive sets of items, with scale scores ranging from 0 to 100 after a linear
transformation. For the global health status/QoL and functioning scales,
higher scores indicate higher levels of function and QoL. For symptom
scales, higher scores indicate worse symptoms or QoL. The prognostic value
of the baseline global health status/QoL, fatigue and physical functioning
scale scores were investigated to analyze their relationship with overall
survival.
schedule of assessments
Patients were scheduled to complete the questionnaires at screening or
baseline, on day 1 of cycle 3, at the ﬁrst 6-weekly evaluation following
completion of chemotherapy, at 6 and 12 months after randomization, and
at the ﬁnal tumor assessment (supplemental Table S1, available at Annals of
Oncology online). Only questionnaires with a date of assessment and
completed within the cut-off date and before further antitumor therapy
were considered evaluable. Only one questionnaire per patient per time
window was analyzed. If a patient completed multiple questionnaires within
a time window, the one completed closest to the scheduled assessment was
analyzed.
statistical analysis
The null hypothesis to be tested with regard to treatment effect was that
there was no difference between the treatment groups. All statistical tests
were performed two sided at the 5% level. No adjustments for multiple
testing were made.
Compliance was deﬁned for each assessment period as the ratio of the
total number of patients with at least one evaluable questionnaire over the
total number of patients for whom a questionnaire was expected.
The intention-to-treat (ITT) population comprised all patients randomly
assigned from countries where the QLQ-C30 and QLQ-H&N35
questionnaires were available. Baseline characteristics were summarized for
patients with at least one evaluable questionnaire for the relevant
instrument. Descriptive statistics were provided for continuous and
categorical variables. A logistic regression model was ﬁtted to test if the
dropout process was missing completely at random. The P value for the
Wald chi-square test was used to test the effect of QoL scores on drop out.
QoL data were analyzed using descriptive statistics for the multi-item and
single-item measures for each treatment group at each of the assessments
points. Least-squares (LS) mean estimates for a treatment by time
interaction, and the difference in the LS means and associated P values,
were obtained from an analysis of variance (ANOVA) model (including
terms for age, gender, histology, KPS, disease stage, EGFR staining, and
a treatment by time interaction) ﬁtted for time points where at least 20% of
patients completing a baseline QoL questionnaire remained in the
population. Results were presented as adjusted and not adjusted for
differences at baseline. Plots of the QoL scores over time were generated for
the global health status/QoL and social functioning scales. Exploratory
analyses assessed per patient best (functioning and generic scales) and worst
(functioning, generic, and symptom scales) QoL summary scores, and the
change between baseline and best and worst scores for each scale, and
compared between treatment arms using the Wilcoxon nonparametric test.
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global health status/QoL scores and social functioning scores against time
by dropout pattern for each treatment group. Only time points where at
least 20% of patients completing a baseline QoL questionnaire remained in
the population were included in the analysis. For prognostic factor analysis,
baseline global health status/QoL, fatigue, and physical functioning scale
scores were split at the median to yield ‘good’ and ‘poor’ scores. Survival
curves were estimated using the Kaplan–Meier technique. The Cox
proportional hazards regression model, stratiﬁed for treatment arm, was
used for multivariate analyses. Signiﬁcance was assessed using the Wald chi-
square test, the HR and its 95% CI values.
results
QoL assessments
A total of 442 patients were randomly assigned to receive
treatment in the EXTREME trial, 220 to platinum–ﬂuorouracil
and 222 to platinum–ﬂuorouracil plus cetuximab. The ITT
subset populations for the QLQ-C30 and QLQ-H&N35
questionnaires comprised 361 patients. No QoL assessments
were conducted in Hungary (n = 43), Ukraine (n = 34), or
Slovakia (n = 4) due to the lack of validated questionnaire
translations.
Results are presented for the assessments at cycle 3 and at 6
months. In general, the numbers of patients contributing data
at the ﬁrst 6-weekly evaluation visit after the end of
chemotherapy, at 12 months, and at the ﬁnal tumor assessment
were insufﬁcient to allow meaningful statistical analysis.
evaluability and compliance
Altogether, 80% of the ITT subset completed at least one
evaluable questionnaire: 291 patients for the QLQ-C30
questionnaire (152 receiving platinum–ﬂuorouracil plus
cetuximab and 139 receiving platinum–ﬂuorouracil alone) and
289 for the QLQ-H&N35 module (152 and 137 patients,
respectively). Of 812 QLQ-C30 and 799 QLQ-H&N35
questionnaires completed, 60% were evaluable.
Compliance rates for both questionnaires were £55% in both
treatment arms at all scheduled post-baseline assessments. The
slightly higher compliance rates seen in the combined
treatment arm can be explained partly by the higher dropout
rate in the chemotherapy-alone arm. For both questionnaires,
only 44% of patients had both an evaluable baseline and a post-
baseline assessment.
The baseline demographics of patients completing at least
one QLQ-C30 questionnaire (Table 1) or QLQ-H&N35
module were generally similar between treatment arms, with
the exceptions that there were more women and slightly fewer
cases of stage IV disease in the cetuximab arm. Among patients
not evaluable for the QoL analysis, there were no marked
differences between the treatment arms in the extent of disease,
the stage of the disease, or the KPS. The baseline demographics
of the QoL population were broadly similar to those in the ITT
population of the EXTREME trial.
QLQ-C30 analysis
At cycle 3 and at 6 months, for each of the functioning and
symptom scales, the mean scores in the cetuximab-containing
arm were generally favorable and were not signiﬁcantly worse
than those in the chemotherapy-alone arm.
At the 6-month assessment, the LS mean for global health
status/QoL was signiﬁcantly higher in the cetuximab-
containing arm compared with the chemotherapy-alone arm
(difference in LS means 12.81 points; P = 0.0399). However, the
difference was not statistically signiﬁcant when the scores were
adjusted for baseline (7.22 points, P = 0.2842). At cycle 3,
differences in the LS means for the physical functioning scale
and the three multi-item symptom scales (fatigue, nausea/
vomiting, and pain) were all signiﬁcantly in favor of cetuximab-
containing arm (Table 2). However, statistical signiﬁcance was
not retained when scores were adjusted for baseline. Figure 1
shows the LS means for global health status/QoL and social
functioning scores over time from baseline to month 6. The
mean worst post-baseline scores for global health status/QoL
and the ﬁve functional scales were not signiﬁcantly different
between the treatment arms. The mean best post-baseline
scores consistently favored the cetuximab-containing arm,
although between-arm differences did not reach statistical
signiﬁcance. For the multi-item symptom scales of fatigue,
Table 1. Baseline characteristics for patients completing evaluable
EORTC QLQ-C30 questionnaires
Characteristic Platinum–
ﬂuorouracil +
cetuximab
(n = 152)
Platinum–
ﬂuorouracil
alone
(n = 139)
Male, n (%) 131 (86) 130 (94)
Female, n (%) 21 (14) 9 (6)
Median age, years (range) 56 (37–80) 56 (33–78)
Karnofsky performance score, n (%)
<80 20 (13) 20 (14)
‡80 132 (87) 119 (86)
Extent of disease, n (%)
Only locoregionally recurrent 76 (50) 70 (50)
Metastatic with or without
locoregional recurrence
76 (50) 69 (50)
Histology, n (%)
Well/moderately differentiated 94 (62) 89 (64)
Poorly differentiated 28 (18) 30 (22)
Not speciﬁed 28 (18) 19 (14)
Missing 2 (1) 1 (1)
Disease stage, n (%)
I–III 57 (38) 42 (30)
IV 92 (61) 91 (65)
Missing 3 (2) 6 (4)
% EGFR staining, n (%)
<40 21 (14) 21 (15)
‡40 123 (81) 107 (77)
Missing 8 (5) 11 (8)
Platinum therapy, n (%)
Cisplatin 96 (63) 86 (62)
Carboplatin 55 (36) 51 (37)
Missing 1 (1) 2 (1)
EGFR, epidermal growth factor receptor; EORTC QLQ-C30, European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30.
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difference between the treatment arms in the mean worst post-
baseline scores or in the mean change from baseline to worst
post-baseline symptom scores. For the six single-item symptom
scales, there were no statistically signiﬁcant differences in the
mean change from baseline to worst post-baseline scores
between treatment groups for any item.
Pattern-mixture analysis revealed a signiﬁcant difference in
the global health status/QoL score between treatment groups in
favor of the cetuximab-containing arm (P = 0.0415). There was
no statistically signiﬁcant difference between the treatment
arms in the social functioning scale.
QLQ-H&N35 analysis
At cycle 3 and at month 6, for every symptom scale, the mean
score in the cetuximab-containing arm was not signiﬁcantly
worse than that in the platinum–5-FU-alone arm.
At cycle 3, differences between the arms in the LS means for
four of the seven multi-item symptom scales (pain and
problems with swallowing, speech, and social eating) were
signiﬁcantly in favor of the cetuximab-containing arm. These
differences remained signiﬁcant after adjusting for the
difference at baseline (Table 3). There were no signiﬁcant
differences between the treatment arms in the mean worst post-
baseline scores for any of the seven multi-item symptom scales
(pain or problems with swallowing, sense, speech, social eating,
social contact, or reduced sexuality). However, there were
statistically signiﬁcant differences in the mean change from
baseline to worst post-baseline scores for pain in favor of
platinum–ﬂuorouracil plus cetuximab (Figure 2). Between-
group differences in favor of the cetuximab group in speech
problems and trouble with social eating were of borderline
signiﬁcance.
For the 11 single-item symptom scales, the only signiﬁcant
difference in the worst post-baseline score between the
treatment arms was for cough: e.g. more than half (55%) of the
patients in the cetuximab-containing arm showed little or no
post-baseline cough compared with 34% receiving platinum–
ﬂuorouracil alone (Table 4). There were no statistically
signiﬁcant differences in the mean change from baseline to
worst post-baseline scores between treatment groups for any
item when ﬁgures were adjusted for baseline.
prognostic value of QoL
Patients with a higher global health status/QoL score at baseline
had a lower risk of death than those with a lower score at
baseline (HR 1.87, 95% CI 1.38–2.53; P < 0.0001). In
multivariate analysis, the baseline factors signiﬁcantly
associated with a poorer survival were KPS <80 (HR 1.98, 95%
CI 1.28–3.04; P = 0.0019), poorly differentiated histology (HR
1.61, 95% CI 1.01–2.56; P = 0.0432), and poor global health
status (HR 1.58, 95% CI 1.05–2.39; P = 0.0287).
missing data patterns
Of the 291 patients with evaluable QLQ-C30 questionnaires,
missing data patterns were intermittent for 80 and monotone (a
complete series of questionnaires before drop out) for 211. For
intermittent missing data, the primary reason documented at
all time points was a random occurrence, unrelated to the QoL
of the patients. For monotone missing data, logistic regression
analysis revealed a nonrandom pattern whereby patients with
a low previous global health status/QoL score had a higher
probability of drop out. The dropout rate was not statistically
signiﬁcantly different between the treatment arms. This effect
was conﬁrmed by pattern-mixture analysis, which showed that
patients in both arms of the study remaining in the study
longer had a better global health status/QoL score at baseline.
discussion
The results of this analysis demonstrate that adding cetuximab
to platinum–ﬂuorouracil does not negatively affect the QoL
of patients with recurrent and/or metastatic SCCHN.
In general, QLQ-C30 summary QoL measures showed
a favorable mean score for platinum–ﬂuorouracil plus
cetuximab and none of the scales showed a signiﬁcantly worse
score for this combination. Longitudinal analyses revealed
Table 2. EORTC QLQ-C30 scores between treatment arms at the cycle 3 assessment for the physical functioning scale and the multi-item symptoms scale
QLQ-C30 scale Statistic Platinum–
ﬂuorouracil
+ cetuximab
(n = 152)
Platinum–
ﬂuorouracil
alone
(n = 139)
Difference in
LS means
(95% CI)
P value Difference in LS
means adjusted
for baseline
(95% CI)
P value
Functioning scales
a
Physical functioning LS mean score (n)
b 67.46 (79) 59.72 (64) 7.74 (0.69 to 14.79) 0.0317 1.23 (26.26 to 8.72) 0.7458
Multi-item symptom scale
Fatigue LS mean score (n)
b 48.12 (80) 58.70 (64) 210.58 (219.24 to 21.92) 0.0169 25.54 (215.11 to 4.03) 0.2547
Nausea and vomiting LS mean score (n)
b 19.99 (79) 26.66 (64) 26.67 (213.27 to 20.06) 0.0478 26.49 (214.15 to 1.18) 0.0965
Pain LS mean score (n)
b 22.93 (80) 35.72 (64) 212.79 (222.35 to 23.24) 0.0090 210.35 (220.99 to 0.29) 0.0566
aThere were no statistically signiﬁcant differences between the treatment arms in the outcomes for the other functioning scales: role, emotional, cognitive, and
social functioning scales. Note that higher scores for physical functioning indicate better physical functioning, whereas higher scores for symptoms indicate
worse symptoms.
bPatients without missing covariates in the multivariate mixed model.
CI, conﬁdence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; LS, least
squares.
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treatment with cetuximab at some individual time points for
global health status, fatigue, nausea/vomiting, and pain, but
differences were not statistically signiﬁcant when adjusted for
baseline. Simpliﬁed analyses, which do not take the dropout
pattern into account, can be subject to bias. In this analysis, the
evaluability rates were rather low, 60%. Compliance rates
were also rather low, with a post-baseline compliance rate of at
Table 3. EORTC QLQ-H&N35 multi-item symptom scale scores at the cycle 3 assessment
QLQ-H&N35 scale Statistic Platinum–
ﬂuorouracil
+ cetuximab
(n = 152)
Platinum–
ﬂuorouracil
alone
(n = 137)
Difference in
LS means
(95% CI)
P value Difference in LS
means adjusted
for baseline
(95% CI)
P value
Pain LS mean score (n)
a 25.79 (80) 37.68 (63) 211.89 (219.79 to 23.99) 0.0034 211.91 (220.70 to 23.11) 0.0083
Swallowing problems LS mean score (n)
a 36.88 (79) 51.01 (60) 214.12 (223.54 to 24.71) 0.0035 214.44 (224.03 to 24.84) 0.0034
Speech problems LS mean score (n)
a 39.15 (78) 51.11 (59) 211.96 (221.16 to 22.76) 0.0112 214.07 (223.25 to 24.89) 0.0029
Social eating problems LS mean score (n)
a 40.31 (79) 50.89 (57) 210.58 (220.60 to 20.57) 0.0384 211.86 (221.67 to 22.04) 0.0182
There were no statistically signiﬁcant differences between the treatment arms in the outcomes for the other items on the multi-item symptom scale: sense,
social contact, and sexuality. Note that higher scores for symptom scales indicate worse symptoms.
aPatients without missing covariates in the multivariate mixed model.
CI, conﬁdence interval; EORTC QLQ-H&N35, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck
35; LS, least squares.
Figure 1. (A) EORTC QLQ-C30 global health status/quality of life and (B) social functioning scores over time from baseline to month 6 by treatment arm
(least-squares means). EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30.
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collection of QoL data was not compulsory in the phase III
trial. The rates of questionnaire evaluability and compliance
were both better in the cetuximab-containing arm than in the
chemotherapy-alone arm. In addition, the dropout rate was
higher for chemotherapy alone. According to logistic
regression and pattern-mixture analyses, the probability of
drop out was dependent on the previous global health status/
QoL score: if these were low, then the probability of drop out
was high.
When the dropout pattern was taken into account, adding
cetuximab to platinum–ﬂuorouracil was associated with
a statistically signiﬁcant improvement in patients’ overall
global health status/QoL score (P = 0.0415), compared with
platinum–ﬂuorouracil alone. A similar analysis of the
QLQ-C30 social functioning scale revealed no statistically
signiﬁcant difference between the treatment arms, suggesting
that the addition of cetuximab to platinum–ﬂuorouracil did
not have a negative effect on patients’ ability to function
normally in a social context [10].
The results from the QLQ-H&N35 module also generally
favored the combined use of platinum–ﬂuorouracil and
cetuximab. At cycle 3, statistically signiﬁcant differences in
favor of the cetuximab arm for pain and problems with
swallowing, speech, and social eating were observed. The results
for pain and problems with swallowing were conﬁrmed by the
changes from baseline to worst post-baseline score. These
results provide evidence to suggest that adding cetuximab to
platinum–ﬂuorouracil helps to alleviate the symptoms
associated with head and neck cancer.
Figure 2. EORTC QLQ-H&N35 multi-item symptom scale scores: mean change from baseline to worst post-baseline scores. EORTC QLQ-H&N35,
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35.
Table 4. EORTC QLQ-H&N35 worst post-baseline single-item symptom scale scores for selected symptoms
Symptom Extent of problem, n (%)
Platinum–ﬂuorouracil + cetuximab (n = 152) Platinum–ﬂuorouracil alone (n = 137)
None at all/a little Quite a bit/very much None at all/a little Quite a bit/very much
Problems with teeth 83 (55) 16 (11) 61 (45) 11 (8)
Problems with opening mouth 68 (45) 33 (22) 48 (35) 27 (20)
Dry mouth 58 (38) 44 (29) 46 (34) 30 (22)
Sticky saliva 50 (33) 50 (33) 35 (26) 40 (29)
Coughing 83 (55) 19 (13) 46 (34) 28 (20)
Feeling ill 74 (49) 28 (18) 50 (36) 25 (18)
EORTC QLQ-H&N35, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35.
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questionnaire [12] and the QLQ-H&N35 module [12, 13] for
assessing QoL in patients with head and neck cancer from
a range of countries has been demonstrated. These instruments
were also used to investigate QoL in patients receiving
cetuximab plus radiotherapy for locally advanced SCCHN [10],
and the results from that analysis are similar to those reported
here, with no adverse effects on global health status/QoL or
social functioning as a result of adding cetuximab to a standard
treatment approach.
In the current analysis, baseline global health status/QoL was
identiﬁed as a statistically signiﬁcant prognostic indicator. This
ﬁnding supports those of other large analyses of patients with
early- and late-stage head and neck cancers [14, 15] and is
consistent with the ﬁnding of Curran et al.’s [10] analysis of
cetuximab in locoregionally advanced disease.
In conclusion, this analysis supports the clinical beneﬁts of
adding a third agent (cetuximab) to ﬁrst-line platinum-based
doublet therapy (i.e. cisplatin or carboplatin in combination
with infusional 5-FU) in patients with recurrent and/or
metastatic SCCHN. Not only does cetuximab plus platinum-
based therapy provide statistically signiﬁcant and clinically
meaningful improvements in overall survival, PFS, and
response and disease control rates compared with platinum-
based chemotherapy alone [2], it does this without adversely
affecting QoL. Moreover, adding cetuximab to this type of
platinum-based chemotherapy provided relief from some of the
symptoms associated with SCCHN. These ﬁndings strongly
support the place of cetuximab plus platinum–ﬂuorouracil as
a new standard ﬁrst-line therapy for recurrent and/or
metastatic SCCHN.
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